Inclisiran treatment reduced LDL-C by 50.7% from baseline within 1 year in patients with hyperlipidemia including HeFH and ASCVD in real-world U.S. infusion centers.
Observational (n=562)
Sí
Does inclisiran reduce LDL-C and what are the out-of-pocket costs for patients initiating therapy in the United States?
Real-world data in the US demonstrates that inclisiran effectively lowers LDL-C within 1 year and is associated with minimal out-of-pocket costs for Medicare patients.
Estimación del efecto: 50.7% reduction
These real-world data demonstrate significant LDL-C reductions within 1 year in patients who initiated inclisiran. Nearly all patients with Medicare had no OOP costs.
Desai et al. (Sun,) conducted a observational in Hyperlipidemia including heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease (n=562). Inclisiran vs. None was evaluated on Percent reduction in low-density lipoprotein cholesterol (LDL-C) from baseline (50.7% reduction). Inclisiran treatment reduced LDL-C by 50.7% from baseline within 1 year in patients with hyperlipidemia including HeFH and ASCVD in real-world U.S. infusion centers.